Pembrolizuamb for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 11 Apr 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.
- 11 Apr 2016 Status changed from not yet recruiting to recruiting.
- 18 Dec 2015 New trial record